An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of two new GnRH implants (AMW Goserelin 3.6 mg Implant and AMW Leuprorelin 3.6 mg Implant) applied every 28 days for 84 days
Latest Information Update: 19 Jul 2011
At a glance
- Drugs Goserelin (Primary) ; Leuprorelin (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors AMW GmbH
Most Recent Events
- 19 Jul 2011 New trial record